Company performance
Add to research
Current Price
as of Jun 18, 2025$2.04
P/E Ratio
N/A
Market Cap
$681.23M
Description
Add to research
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
Metrics
Add to research
Overview
- HQSan Carlos, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerIOVA
- Price$2.04+0.99%
Trading Information
- Market cap$681.23M
- Float81.30%
- Average Daily Volume (1m)11,578,178
- Average Daily Volume (3m)13,326,044
- EPS-$1.23
Company
- Revenue$212.68M
- Rev growth (1yr)6,798.46%
- Net income-$116.16M
- Gross margin-12.32%
- EBITDA margin-223.33%
- EBITDA-$110.16M
- EV$768.60M
- EV/Revenue3.61
- P/EN/A
- P/S3.10
- P/B0.89
- Debt/Equity7.00
Documents
Add to research
SEC Filings
Earnings Calls